Další formáty:
BibTeX
LaTeX
RIS
@proceedings{60393,
author = {Dostálová, Lenka and Ledererová, Aneta and Peschelová, Helena and Loja, Tomáš and Šmída, Michal},
booktitle = {CRISPR as a research tool in cancer and regenerative medicine, Stockholm, Švédsko},
keywords = {CD20 antigen; mAb therapy; rituximab},
language = {eng},
title = {Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation.},
url = {https://is.muni.cz/auth/publication/2356319/CRISPR_Symposium2023_Abstracts.pdf},
year = {2023}
}
TY - CONF
ID - 60393
AU - Dostálová, Lenka - Ledererová, Aneta - Peschelová, Helena - Loja, Tomáš - Šmída, Michal
PY - 2023
TI - Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation.
KW - CD20 antigen
KW - mAb therapy
KW - rituximab
UR - https://is.muni.cz/auth/publication/2356319/CRISPR_Symposium2023_Abstracts.pdf
N2 - CD20 antigen has been used as a target of monoclonal antibodies (mAb) such as rituximab (RTX) in the therapy of B-cell malignancies for more than two decades. However, malignant B cells downregulate CD20 on their surface, resulting in mAb resistance and therapy failure. Therefore, it is crucial to investigate the CD20 regulation to enhance the efficacy of anti CD20 mAb. This project aimed to perform CRISPR/Cas9 knockout screening to identify genes whose disruption restores CD20 surface expression. To create a model mimicking the situation in patients who have developed resistance to mAb therapy, we generated RTX-resistant CD20-low B-cell line by chronic exposure to rituximab. These cells were transduced by the GeCKO lentiviral library to obtain a collection of single-gene knockouts. After 2.5-week cultivation, the top 5% of cells with the highest expression of CD20 were sorted out. Using next-generation sequencing, we identified gene knockouts responsible for CD20 upregulation.
ER -
DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Helena PESCHELOVÁ, Tomáš LOJA a Michal ŠMÍDA. Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. In \textit{CRISPR as a research tool in cancer and regenerative medicine, Stockholm, Švédsko}. 2023.
|
